ATE537187T1 - Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung - Google Patents
Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendungInfo
- Publication number
- ATE537187T1 ATE537187T1 AT05757060T AT05757060T ATE537187T1 AT E537187 T1 ATE537187 T1 AT E537187T1 AT 05757060 T AT05757060 T AT 05757060T AT 05757060 T AT05757060 T AT 05757060T AT E537187 T1 ATE537187 T1 AT E537187T1
- Authority
- AT
- Austria
- Prior art keywords
- class
- antigen
- production
- composition containing
- vaccine composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0403848A FR2868781B1 (fr) | 2004-04-13 | 2004-04-13 | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
PCT/FR2005/000894 WO2005103079A1 (fr) | 2004-04-13 | 2005-04-13 | Composition de vaccin comprenant un ligan cmh de classe ii couple a un antigene, procede de preparation et utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE537187T1 true ATE537187T1 (de) | 2011-12-15 |
Family
ID=34944934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05757060T ATE537187T1 (de) | 2004-04-13 | 2005-04-13 | Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080003235A1 (de) |
EP (1) | EP1735344B1 (de) |
JP (1) | JP5000481B2 (de) |
CN (1) | CN101010341A (de) |
AT (1) | ATE537187T1 (de) |
CA (1) | CA2560891C (de) |
FR (1) | FR2868781B1 (de) |
WO (1) | WO2005103079A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2902101B1 (fr) | 2006-06-12 | 2012-12-28 | Scras | Peptides a activite anti-proliferative |
EP2044949A1 (de) | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
CN108472320A (zh) * | 2015-10-09 | 2018-08-31 | 创祐生技股份有限公司 | 抗癌疫苗组合 |
CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
WO2022237685A1 (zh) * | 2021-05-08 | 2022-11-17 | 武汉友芝友生物制药股份有限公司 | Lag-3蛋白突变体及其制备和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE352617T1 (de) * | 1994-05-06 | 2007-02-15 | Roussy Inst Gustave | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
WO1998023741A1 (fr) | 1996-11-28 | 1998-06-04 | Institut Gustave Roussy | Mutants de la proteine lag-3, leur expression et utilisation |
EP0893507A1 (de) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs |
EP1002110B2 (de) * | 1997-08-05 | 2009-07-29 | Stressgen Biotechnologies Corporation | Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine |
-
2004
- 2004-04-13 FR FR0403848A patent/FR2868781B1/fr not_active Expired - Fee Related
-
2005
- 2005-04-13 JP JP2007507816A patent/JP5000481B2/ja not_active Expired - Fee Related
- 2005-04-13 CN CNA2005800111130A patent/CN101010341A/zh active Pending
- 2005-04-13 WO PCT/FR2005/000894 patent/WO2005103079A1/fr not_active Application Discontinuation
- 2005-04-13 CA CA2560891A patent/CA2560891C/fr not_active Expired - Fee Related
- 2005-04-13 AT AT05757060T patent/ATE537187T1/de active
- 2005-04-13 US US11/547,452 patent/US20080003235A1/en not_active Abandoned
- 2005-04-13 EP EP05757060A patent/EP1735344B1/de not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
EP1735344B1 (de) | 2011-12-14 |
FR2868781A1 (fr) | 2005-10-14 |
CA2560891C (fr) | 2013-08-20 |
JP5000481B2 (ja) | 2012-08-15 |
CA2560891A1 (fr) | 2005-11-03 |
JP2008501635A (ja) | 2008-01-24 |
EP1735344A1 (de) | 2006-12-27 |
US20080003235A1 (en) | 2008-01-03 |
CN101010341A (zh) | 2007-08-01 |
FR2868781B1 (fr) | 2008-02-22 |
WO2005103079A1 (fr) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123400T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
ATE537187T1 (de) | Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung | |
DE602006020056D1 (de) | Dimercaptanterminierte polythioetherpolymere und verfahren zu ihrer herstellung und verwendung | |
ATE381564T1 (de) | Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
CY1113206T1 (el) | Μεθοδος παρασκευης προϊοντος συζευξης αντισωματος maytansinoid | |
ATE521708T1 (de) | Chimärische, hybrid- und tandem-polypeptide von meningococcus nmb1870 | |
ATE490256T1 (de) | Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE382049T1 (de) | Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
ATE488623T1 (de) | Polymere strukturen und verfahren zu deren herstellung | |
DE502006005581D1 (de) | Ukmischungen, ein verfahren zu deren herstellung, verfahren zur herstellung von verbund-formteilen und deren verwendung | |
SG170091A1 (en) | Anti-5t4 antibodies and uses thereof | |
TW200741000A (en) | Method of producing lymphocytes | |
DE602006013151D1 (de) | Verfahren zur herstellung von polymermaleimiden | |
ATE496041T1 (de) | 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel | |
ATE497509T1 (de) | Elektrosterisch stabilisierte wässrige polyurethan-harze, verfahren zu ihrer herstellung und deren verwendung | |
ATE505535T1 (de) | Verfahren zur herstellung stabiler b-lymphozyten | |
ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
DE602006010934D1 (de) | Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika | |
ATE372336T1 (de) | Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen | |
NO20083609L (no) | Fremgangsmater og sammensetninger for malrettet-RELT | |
ATE380191T1 (de) | Gemischtes olanzapinsolvat, verfahren zu dessen herstellung und verfahren zur herstellung von olanzapin-form i daraus | |
DE602004029319D1 (de) | Verbindung mit phoshorylcholingruppe, dessen polymer und verfahren zu dessen herstellung | |
ATE487706T1 (de) | Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
ATE388936T1 (de) | 9-chloro-15-deoxyprostaglandinderivate, verfahren zu ihrer herstellung und deren verwendung als medikamente | |
DE602004026157D1 (de) | Proteinkomplex, verfahren zu dessen herstellung und verwendung davon |